ClinicalTrials.gg
CompletedNCT06481085Updated Jul 28, 2025

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

A Phase 2 interventional study of HDM1002 50 mg and HDM1002 100 mg in Type 2 Diabetes, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Completed at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. — 7 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Huadong Medicine Co., Ltd..

Enrollment
7th of 10
324 · median 395
Started
2024
with 1 other
Phase 2
2 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., this one is the 7th largest by enrollment, is one of 2 that started in 2024, is one of 2 in phase 2, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise.

Read the detailed description

This phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel group study aims to assess the efficacy and safety of HDM1002 tablets in adult participants with T2DM inadequately controlled on metformin monotherapy or diet and exercise alone. At least 80% of the enrolled participants are required to be on metformin prior to screening. A total of 318 participants will be included in this study, and will be stratified according to baseline glycated hemoglobin (HbA1c) (≤ 8.5% or > 8.5%) and background diabetes treatment (metformin or diet and exercise alone). For cohort A to cohort E, approximately 293 participants will be randomized in a 57:57:57:65:57 ratio to receive different doses of HDM1002 or placebo. In addition, an open-label design will be used in cohort F to explore the efficacy and safety of HDM1002 tablets administered in 200 mg twice daily. About 25 participants will be enrolled in cohort F, all of which will receive HDM1002 tablets. Following the screening period to confirm eligibility up to 2-weeks, the study will consist of a 2-week placebo run-in period (participants with diet and exercise alone) or a 6-week metformin run-in period (participants with metformin prior to screening) prior to randomization on Day 1. The treatment period will be 12 weeks, followed by an approximate 4-week follow-up. Dosing will occur with or without food once daily or twice daily, and up to 4 weeks of dose titration regimen will be adopted to maximize tolerability of HDM1002.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • HDM1002 tablet
  • type 2 diabetes
  • Glucagon-Like Peptide-1 Receptor Agonists
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 75 years of age (inclusive).
  2. Have been diagnosed with type 2 diabetes mellitus (T2DM) for at least 3 months based on the World Health Organization (WHO 1999) and meets one of the following conditions:

    • Participants treated with a stable dose of metformin (with maintenance dose of at least 1500 mg/day or a maximally tolerated dose not less than 1000 mg) for at least 6 weeks prior to screening; and must be stable for at least 12 weeks prior to randomization.
    • Participants on diet and exercise alone for at least 12 weeks prior to screening will be limited to ≤20% of total participant population.
  3. ≥7.5% and ≤10.5% at screening as assessed by the local laboratory, and HbA1c ≥7.5% and ≤10.5% prior to randomization as assessed by the specified central laboratory.
  4. Having a (BMI) of 22.5 to 40.0 kg/m2, inclusive.
  5. Female participants of and male participants must agree to use highly effective method from the day of signing the form (ICF) and until 30 days (female) or 90 days (male) after the final dose administration.
  6. Able to understand and comply with protocol requirements, agree to maintain the same dietary and exercise habits throughout the trial, be willing to complete the trial in strict compliance with the clinical trial protocol and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with type 1 diabetes mellitus (including latent diabetes in adults), special types of diabetes or gestational diabetes mellitus.
  2. Evidence of acute complications of diabetes (e.g., diabetic ketoacidosis, diabetic lactosidosis, or hyperosmolar nonketotic coma) within 6 months before signing the ICF.
  3. History of level 3 hypoglycemia (as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) , or history of asymptomatic hypoglycaemic episodes within 6 months prior to signing the ICF.
  4. Severe infection within 4 weeks prior to screening and may affect glucose control in the opinion of the investigator.
  5. Have a known self or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia or multiple endocrine neoplasia type II (MEN2).
  6. Evidence of uncontrolled hypothyroidism or hyperthyroidism as judged by the investigator at the time of signing the ICF, or on a stable dose of medication therapy less than 3 months, or having been expected to require dose adjustments throughout the trial.
  7. History of acute or chronic pancreatitis, or any high-risk factor which may lead to pancreatitis; or have symptomatic gallbladder disease within 6 months before signing the ICF.
  8. Any condition or disease possibly affecting gastric emptying or nutrients absorption in the opinion of the investigator, such as history of bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, etc.
  9. Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg under stable treatments of antihypertensive drugs at screening; or previous evidence of renal artery stenosis or unstable blood pressure (including postural hypotension).
  10. Have had any of the following within 6 months before signing the ICF:

    • unstable angina;
    • heart failure (, class III or IV);
    • myocardial infarction (MI);
    • coronary artery bypass grafting or percutaneous coronary intervention;
    • Uncontrolled severe arrhythmias (including: ventricular tachycardia, ventricular fibrillation, atrial fibrillation, second to third degree atrioventricular block, sick sinus node syndrome, pre-excitation syndrome, etc.);
    • cerebrovascular accident (including stroke or ).
  11. Have a history of proliferative diabetic retinopathy and/or diabetic maculopathy, or evidence of other severe retinopathy that requires immediate treatment intervention.
  12. Have a known history of liver disease, including: acute or chronic active liver disease (except non-alcoholic steatohepatitis) such as active , ; or primary biliary cholangitis.
  13. Have evidence of a significant, active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that, in the opinion of the investigator, requires concurrent treatment with systemic during the trial.
  14. Evidence of any with 5 years before signing the ICF (except for basal cell carcinoma that has received curative treatment and is considered cured).
  15. Self-reported or documented change in body weight of ≥5% within 3 months before signing the ICF.
  16. Having used a Glucagon-like peptide-1 (GLP-1) analogue within 6 months prior to signing the ICF; or previous discontinuation of a GLP-1 analogue due to safety/tolerability or lack of efficacy.
  17. Estimated (eGFR) \< 45 mL/min.
  18. Positive result on HBsAg, anti-hepatitis C virus (HCV) antibodies, anti-immunodeficiency virus () antibodies, or a positive test result for antibodies to syphilis spirochetes.
  19. History of alcohol abuse (i.e., drinking more than 14 standard units of alcohol per week for men and 7 standard units of alcohol per week for women, with 1 standard unit containing 14 g of alcohol, such as 360 mL of beer or 45 mL of spirits with alcohol content of 40% or 150 mL of wine) or drug addiction within one year before signing the ICF; or presence of a psychiatric disorder that, in the opinion of the investigator, could interfere with participation in the study (e.g., depression).
  20. Pregnancy or lactation.
  21. Known allergy to any components of the drug, metformin or its .
  22. Have any of the following conditions: an investigator or sub-investigator, or a research assistant, or a pharmacist, or a study coordinator, or other staff member directly involved in the study, or any person who is dependent on the study site, the investigator, or the sponsor (such as employees or their immediate family member).
  23. Enrolled in or participated in any other clinical study within 3 months (or within 5 times the elimination half-life, whichever is longer) prior to signing the ICF (except for subjects who signed written without any intervention of investigational product).
  24. Any other condition considered by the investigator which is not suitable for participating in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    HDM1002 50 mg

    Participants received 50 mg HDM1002 administered orally once daily (QD)

    Drug: HDM1002 50 mg

  • Experimental
    HDM1002 100 mg

    Participants received maintenance dose of 100 mg with dose escalation starting from 50 mg HDM1002 administered orally once daily (QD)

    Drug: HDM1002 100 mg

  • Experimental
    HDM1002 200 mg

    Participants received maintenance dose 200 mg with dose escalation starting from 50 mg, 100 mg and then 200 mg HDM1002 administered orally QD

    Drug: HDM1002 200 mg

  • Experimental
    HDM1002 400 mg

    Participants received maintenance dose 200 mg with dose escalation starting from 50 mg, 100 mg, 200 mg and then 400 mg HDM1002 administered orally QD

    Drug: HDM1002 400 mg

  • Placebo comparator
    Placebo

    Participants received matching placebo administered orally QD

    Drug: Placebo

  • Experimental
    HDM1002 200 mg bid

    Participants received maintenance dose 400 mg with dose escalation starting from 25 mg, 50 mg, 100 mg and then 200 mg HDM1002 administered orally twice daily (BID)

    Drug: HDM1002 200 mg BID

Interventions

  • HDM1002 tablets, 50 mg once daily, 12 weeks

    Also known as: HDM1002

  • HDM1002 tablets, 100 mg once daily, 12 weeks

    Also known as: HDM1002

  • HDM1002 tablets, 200 mg once daily, 12 weeks

    Also known as: HDM1002

  • HDM1002 tablets, 400 mg once daily, 12 weeks

    Also known as: HDM1002

  • HDM1002 tablets, 200 mg twice daily, 12 weeks

    Also known as: HDM1002

  • DrugPlacebo

    Matching placebo will be provided

    Also known as: Matching placebo for group A to group E

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at Week 12

    HbA1c can be used as a diagnostic test for diabetes and is a widely recognized objective measure of glycemic control

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in HbA1c at Week 4, Week 8

    HbA1c can be used as a diagnostic test for diabetes and is a widely recognized objective measure of glycemic control

    Time frame: Baseline, Week 4, Week 8

  2. Percentage of Participants With an HbA1c target value of < 7.0% or ≤ 6.5%

    The target HbA1c level for people with diabetes is usually less than 7%.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Fasting plasma Glucose

    The fasting plasma glucose measures the levels of glucose in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Postprandial 2-hour Glucose (PPG2h), Area Under the Curve of Plasma Glucose (AUC0-4h, Glucose), C-Peptide (AUC0-4h, C-peptide), Insulin (AUC0-4h, Insulin), and Glucagon (AUC0-4h, Glucagon)

    These indicators were assessed using the mixed-meal tolerance test

    Time frame: Baseline, Week 12

  5. Change From Baseline in Fasting C-Peptide, Fasting Insulin, and Fasting Glucagon

    C-Peptide, Fasting Insulin, and Fasting Glucagon were measured at planned time points

    Time frame: Baseline, Week 12

  6. Change From Baseline in Homeostasis Model Assessment of β-Cell Function (HOMA-β) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

    HOMA-IR and HOMA-β are commonly used to estimate insulin resistance and beta cell function.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Fasting Lipid Profiles, including: Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Total Cholesterol (TC), Non-HDL-C and Lipoprotein (a) [Lp(a)]

    Fasting Lipid Profiles were measured at planned time points.

    Time frame: Baseline, Week 12

  8. Change From Baseline in Systolic and Diastolic Blood Pressure

    Blood Pressure was measured using an automated device

    Time frame: Baseline, Week 12

  9. Change From Baseline in Body Weight

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 12

  10. Percentage of Participants Achieving Weight Loss ≥ 5% and ≥ 10%

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 12

  11. Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs]), Adverse Events of Special Interest (AESI), Incidence and Severity of Hypoglycaemic Events, etc.

    A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.

    Time frame: Baseline Through Week 16

  12. Number of Participants with Clinical Laboratory Abnormalities, and Abnormalities in Vital Signs, Physical Examination and Electrocardiogram

    Vital signs (blood pressure, pulse rate, body temperature, respiratory rate), physical examination, ECG and clinical laboratory evaluations (hematology, clinical chemistry, coagulation, urinalysis, calcitonin, serum amylase and lipase)

    Time frame: Baseline Through Week 16

Other outcomes

  1. Change From Baseline in Glycaemic Indicators According to Treatment Background ( Metformin or Diet and Exercise Alone)

    Glycaemic Indicators include HbA1c (%), fasting plasma glucose (mmol/L) and 2-hour postprandial blood glucose (mmol/L)

    Time frame: Baseline, Week 12

  2. Change From Baseline in Body Weight According to Treatment Background ( Metformin or Diet and Exercise Alone)

    Weight in kilograms

    Time frame: Baseline, Week 12

  3. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    PK parameters including: Maximum plasma concentration (Cmax), Minumum plasma concentration (Cmin), Time to maximum plasma concentration (Tmax), AUCtau, Area under the curve from time 0 to 24 h(AUC0-24h)

    Time frame: Baseline, Day 71

07

Study locations

31 sites
  • The Chinese People's Liberation Army General Hospital
    Beijing, Beijing Municipality 100039, China
  • Beijing Chaoyang Hospital Affiliated to Capital Medical University
    Beijing, China
  • Peking University Shougang Hospital
    Beijing, China
  • Cangzhou Central Hospital
    Cangzhou, China
  • The Second Hospital of Jilin University
    Changchun, China
  • The Fourth Hospital of Changsha City
    Changsha, China
  • The Third Hospital of Changsha City
    Changsha, China
  • Chengdu Second People's Hospital
    Chengdu, China
  • The Affiliated Hospital of Chengdu University
    Chengdu, China
  • Three Gorges Hospital Affiliated to Chongqing University
    Chongqing, China
  • The First Hospital of Handan City
    Handan, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, China
  • Huizhou Central People's Hospital
    Huizhou, China
  • Huzhou Central Hospital
    Huzhou, China
  • Jinan Central Hospital
    Jinan, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, China
  • The Third People's Hospital of Luoyang City
    Luoyang, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, China
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, China
  • The First People's Hospital of Nanyang City
    Nanyang, China
  • Panjin Liaohe Oilfield General Hospital
    Panjin, China
  • The First Hospital of Qinhuangdao City
    Qinhuangdao, China
  • Suzhou Municipal Hospital
    Suzhou, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, China
  • Tonghua Central Hospital
    Tonghua, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
  • Xuzhou Cancer Hospital
    Xuzhou, China
  • Yueyang People's Hospital
    Yueyang, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in May 2025, 11 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jul 1, 2024
StartActual
Jun 27, 2024
Primary completionActual
May 30, 2025
CompletionActual
Jun 30, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06481085
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jun 27, 2024
Primary completion
May 30, 2025
Completion
Jun 30, 2025
Last update
Jul 28, 2025

Study contacts

Yiming Mu, Ph.D
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion